publications-banner
Information about pipeline products
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
PublicationView
T-DXd
Trastuzumab deruxtecan in anti-human epidermal growth factor receptor 2 treatment-naive patients with human epidermal growth factor receptor 2-low gastric or gastroesophageal junction adenocarcinoma: Exploratory cohort results in a phase II trial
Edoxaban
Edoxaban in cardiovascular medicine from scientific evidence to clinical practice
T-DXd
Effect of trastuzumab deruxtecan on QT/QTC interval and pharmacokinetics in HER2-positive or HER2-low metastatic/unresectable breast cancer
HER3-DXd
Population pharmacokinetics of patritumab deruxtecan in patients with solid tumors
Pexidartinib
Pexidartinib provides modest pain relief in patients with tenosynovial giant cell tumor: Results from ENLIVEN
T-DXd
Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies
T-DXd
Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer.
Pexidartinib
Results from phase I extension study assessing pexidartinib treatment in six cohorts with solid tumors including TGCT, and abnormal CSF1 transcripts in TGCT
HER3-DXd
Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer